Bioventus Shares Slide After Third-Quarter Sales Miss and Lower Annual Outlook

what happened

Shares of Bioventus fell in after-hours trading on Monday after the company lowered its revenue outlook and reported third-quarter sales below analyst forecasts. According to Dow Jones Newswires, the stock dropped 11% to $11.75. During the regular session it closed down 1.3% at $13.15, though it had still gained 77% year to date through the close.

The company posted a profit of $6 million, or 8 cents a share, versus $3.2 million, or 5 cents, a year earlier. Excluding certain one-time items, adjusted earnings came to 17 cents a share, beating the 15 cents expected by analysts polled by FactSet. Net sales rose to $142.4 million from $138.7 million, but analysts had expected $149.5 million.

For the full year, Bioventus now projects net sales of $590 million to $595 million, down from its previous range of $600 million to $610 million. Analysts currently expect $604.8 million. The company kept its adjusted earnings guidance of 75 to 79 cents a share, in line with the 78 cents analysts are forecasting.

why it matters

The signal for investors is mixed to weak: the company missed revenue expectations and trimmed its sales target at the same time, so the market will focus on the quality of growth rather than the one-time earnings beat. The reaffirmed profit guidance softens the picture, but the sales trend remains the key question.

market impact

Bioventus shares: weak sales and a lower outlook pressure the stock price

• ▼Bioventus shares pressure down — sales below expectations and a reduced 2026 net sales forecast

tags

instruments